Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 8 de 8
Filtrer
Plus de filtres











Base de données
Gamme d'année
1.
Mol Med Rep ; 16(6): 9043-9050, 2017 Dec.
Article de Anglais | MEDLINE | ID: mdl-28990095

RÉSUMÉ

Gastric cancer is a leading cause of cancer­associated mortality worldwide. In studies on the mechanisms of antigastric cancer drugs, autophagy and endoplasmic reticulum (ER) stress have been demonstrated to serve an active role in gastric cancer. The organic extract of Periplaneta americana (also termed American Cockroach), which is named Kangfuxin (KFX) in China, has been used clinically as a traditional Chinese medicine against disorders, including stomach bleeding, gastric ulcers, tuberculosis, burns and trauma. However, the role of KFX and its mechanism in gastric cancer remains to be elucidated. The present study aimed to determine the effects of KFX in vitro against cultured the human carcinoma SGC­7901 cell line, and to explore the potential mechanism of the anticancer effects of KFX in gastric cancer. SGC­7901 cells were treated with different concentrations of KFX for varying amounts of time. As a result, KFX treatment decreased the ratio of apoptosis regulators Bcl­2/Bax, activated ER stress and induced significant apoptosis in SGC­7901 cells. Furthermore, KFX was able to restore the ER stress activation blocked by 4­phenylbutyrate. In addition, KFX activated autophagy in SGC­7901 cells. These results demonstrated that ER stress, autophagy and the apoptosis­inducing effects of KFX in SGC­7901 cells may achieve promising anticancer effects in numerous other types of cancer. In particular, ER stress may serve an essential role in KFX­induced anticancer effects on gastric carcinoma and a secondary role in autophagy.


Sujet(s)
Apoptose/effets des médicaments et des substances chimiques , Autophagie/effets des médicaments et des substances chimiques , Stress du réticulum endoplasmique/effets des médicaments et des substances chimiques , Matière médicale/pharmacologie , Tumeurs de l'estomac/anatomopathologie , Autophagosomes/effets des médicaments et des substances chimiques , Autophagosomes/métabolisme , Autophagosomes/ultrastructure , Lignée cellulaire tumorale , Prolifération cellulaire/effets des médicaments et des substances chimiques , Humains , Modèles biologiques , Régulation positive/effets des médicaments et des substances chimiques
2.
Int J Mol Sci ; 17(3): 284, 2016 Feb 25.
Article de Anglais | MEDLINE | ID: mdl-26927073

RÉSUMÉ

Pressure ulcer is a complex and significant health problem in long-term bedridden patients, and there is currently no effective treatment or efficient prevention method. Furthermore, the molecular mechanisms and pathogenesis contributing to the deep injury of pressure ulcers are unclear. The aim of the study was to explore the role of endoplasmic reticulum (ER) stress and Akt/GSK3ß signaling in pressure ulcers. A model of pressure-induced deep tissue injury in adult Sprague-Dawley rats was established. Rats were treated with 2-h compression and subsequent 0.5-h release for various cycles. After recovery, the tissue in the compressed regions was collected for further analysis. The compressed muscle tissues showed clear cellular degenerative features. First, the expression levels of ER stress proteins GRP78, CHOP, and caspase-12 were generally increased compared to those in the control. Phosphorylated Akt and phosphorylated GSK3ß were upregulated in the beginning of muscle compression, and immediately significantly decreased at the initiation of ischemia-reperfusion injury in compressed muscles tissue. These data show that ER stress may be involved in the underlying mechanisms of cell degeneration after pressure ulcers and that the Akt/GSK3ß signal pathway may play an important role in deep tissue injury induced by pressure and ischemia/reperfusion.


Sujet(s)
Stress du réticulum endoplasmique , Muscles squelettiques/métabolisme , Escarre/métabolisme , Lésion d'ischémie-reperfusion/métabolisme , Animaux , Caspase-12/génétique , Caspase-12/métabolisme , Glycogen Synthase Kinase 3/génétique , Glycogen Synthase Kinase 3/métabolisme , Glycogen synthase kinase 3 beta , Protéines du choc thermique/génétique , Protéines du choc thermique/métabolisme , Mâle , Muscles squelettiques/vascularisation , Muscles squelettiques/anatomopathologie , Escarre/étiologie , Escarre/anatomopathologie , Protéines proto-oncogènes c-akt/génétique , Protéines proto-oncogènes c-akt/métabolisme , Rats , Rat Sprague-Dawley , Lésion d'ischémie-reperfusion/complications , Lésion d'ischémie-reperfusion/anatomopathologie , Transduction du signal , Facteur de transcription CHOP/génétique , Facteur de transcription CHOP/métabolisme , Régulation positive
3.
Mol Neurobiol ; 53(7): 4375-86, 2016 09.
Article de Anglais | MEDLINE | ID: mdl-26232067

RÉSUMÉ

Clinical translation of growth factor therapies faces multiple challenges; the most significant one is the short half-life of the naked protein. Gelatin nanostructured lipid carriers (GNLs) had previously been used to encapsulate the basic fibroblast growth factor to enhance the functional recovery in hemiparkinsonian rats. In this research, we comparatively study the enhanced therapy between nerve growth factor (NGF) loaded GNLs (NGF-GNLs) and NGF only in spinal cord injury (SCI). The effects of NGF-GNLs and NGF only were tested by the Basso-Beattie-Bresnahan (BBB) locomotion scale, inclined plane test, and footprint analysis. Western blot analysis and immunofluorescent staining were further performed to identify the expression of ER stress-related proteins, neuron-specific marker neuronal nuclei (NeuN), and growth-associated protein 43 (GAP43). Correlated downstream signals Akt/GSK-3ß and ERK1/2 were also analyzed with or without inhibitors. Results showed that NGF-GNLs, compared to NGF only, enhanced the neuroprotection effect in SCI rats. The ER stress-induced apoptosis response proteins CHOP, GRP78 and caspase-12 inhibited by NGF-GNL treatment were more obvious. Meanwhile, NGF-GNLs in the recovery of SCI are related to the inhibition of ER stress-induced cell death via the activation of downstream signals PI3K/Akt/GSK-3ß and ERK1/2.


Sujet(s)
Apoptose/effets des médicaments et des substances chimiques , Stress du réticulum endoplasmique/effets des médicaments et des substances chimiques , Gélatine/composition chimique , Lipides/composition chimique , Nanostructures/composition chimique , Facteur de croissance nerveuse/pharmacologie , Récupération fonctionnelle/effets des médicaments et des substances chimiques , Traumatismes de la moelle épinière/physiopathologie , Animaux , Survie cellulaire/effets des médicaments et des substances chimiques , Modèles animaux de maladie humaine , Vecteurs de médicaments/composition chimique , Extracellular Signal-Regulated MAP Kinases/métabolisme , Femelle , Nanostructures/ultrastructure , Facteur de croissance nerveuse/usage thérapeutique , Neurones/effets des médicaments et des substances chimiques , Neurones/métabolisme , Neuroprotection/effets des médicaments et des substances chimiques , Cellules PC12 , Protéines proto-oncogènes c-akt/métabolisme , Rats , Rat Sprague-Dawley , Transduction du signal/effets des médicaments et des substances chimiques , Traumatismes de la moelle épinière/traitement médicamenteux , Régulation positive/effets des médicaments et des substances chimiques
4.
Biomed Res Int ; 2015: 808202, 2015.
Article de Anglais | MEDLINE | ID: mdl-26347885

RÉSUMÉ

Growth factors are a class of cytokines that stimulate cell growth and are widely used in clinical practice, such as wound healing, revascularization, bone repair, and nervous system disease. However, free growth factors have a short half-life and are instable in vivo. Therefore, the search of excellent carriers to enhance sustained release of growth factors in vivo has become an area of intense research interest. The development of controlled-release systems that protect the recombinant growth factors from enzymatic degradation and provide sustained delivery at the injury site during healing should enhance the growth factor's application in tissue regeneration. Thus, this study reviews current research on commonly used carriers for sustained release of growth factors and their sustained release effects for preservation of their bioactivity and their accomplishment in tissue engineering approaches.


Sujet(s)
Implant pharmaceutique , Protéines et peptides de signalisation intercellulaire , Régénération/effets des médicaments et des substances chimiques , Médecine régénérative/méthodes , Ingénierie tissulaire/méthodes , Animaux , Préparations à action retardée/composition chimique , Préparations à action retardée/usage thérapeutique , Implant pharmaceutique/composition chimique , Implant pharmaceutique/usage thérapeutique , Humains , Protéines et peptides de signalisation intercellulaire/composition chimique , Protéines et peptides de signalisation intercellulaire/usage thérapeutique
5.
Biomed Res Int ; 2015: 730139, 2015.
Article de Anglais | MEDLINE | ID: mdl-25685806

RÉSUMÉ

Growth factors are involved in the regulation of hair morphogenesis and cycle hair growth. The present study sought to investigate the hair growth promoting activities of three approved growth factor drugs, fibroblast growth factor 10 (FGF-10), acidic fibroblast growth factor (FGF-1), and basic fibroblast growth factor (FGF-2), and the mechanism of action. We observed that FGFs promoted hair growth by inducing the anagen phase in telogenic C57BL/6 mice. Specifically, the histomorphometric analysis data indicates that topical application of FGFs induced an earlier anagen phase and prolonged the mature anagen phase, in contrast to the control group. Moreover, the immunohistochemical analysis reveals earlier induction of ß-catenin and Sonic hedgehog (Shh) in hair follicles of the FGFs-treated group. These results suggest that FGFs promote hair growth by inducing the anagen phase in resting hair follicles and might be a potential hair growth-promoting agent.


Sujet(s)
Facteurs de croissance fibroblastique/métabolisme , Fibroblastes/métabolisme , Régulation de l'expression des gènes/physiologie , Follicule pileux/croissance et développement , Protéines Hedgehog/biosynthèse , bêta-Caténine/biosynthèse , Animaux , Facteurs de croissance fibroblastique/pharmacologie , Fibroblastes/cytologie , Régulation de l'expression des gènes/effets des médicaments et des substances chimiques , Souris
7.
PLoS One ; 8(4): e59966, 2013.
Article de Anglais | MEDLINE | ID: mdl-23565178

RÉSUMÉ

Hypertrophic scars (HTS) and keloids are challenging problems. Their pathogenesis results from an overproduction of fibroblasts and excessive deposition of collagen. Studies suggest a possible anti-scarring effect of basic fibroblast growth factor (bFGF) during wound healing, but the precise mechanisms of bFGF are still unclear. In view of this, we investigated the therapeutic effects of bFGF on HTS animal model as well as human scar fibroblasts (HSF) model. We show that bFGF promoted wound healing and reduced the area of flattened non-pathological scars in rat skin wounds and HTS in the rabbit ear. We provide evidence of a new therapeutic strategy: bFGF administration for the treatment of HTS. The scar elevation index (SEI) and epidermal thickness index (ETI) was also significantly reduced. Histological reveal that bFGF exhibited significant amelioration of the collagen tissue. bFGF regulated extracellular matrix (ECM) synthesis and degradation via interference in the collagen distribution, the α-smooth muscle actin (α-SMA) and transforming growth factor-1 (TGF-ß1) expression. In addition, bFGF reduced scarring and promoted wound healing by inhibiting TGFß1/SMAD-dependent pathway. The levels of fibronectin (FN), tissue inhibitor of metalloproteinase-1 (TIMP-1) collagen I, and collagen III were evidently decreased, and matrix metalloproteinase-1 (MMP-1) and apoptosis cells were markedly increased. These results suggest that bFGF possesses favorable therapeutic effects on hypertrophic scars in vitro and in vivo, which may be an effective cure for human hypertrophic scars.


Sujet(s)
Facteur de croissance fibroblastique de type 2/pharmacologie , Cicatrisation de plaie/effets des médicaments et des substances chimiques , Cicatrisation de plaie/physiologie , Actines/métabolisme , Animaux , Antigènes CD/métabolisme , Antigènes de différenciation des myélomonocytes/métabolisme , Apoptose/effets des médicaments et des substances chimiques , Cicatrice hypertrophique/traitement médicamenteux , Collagène de type I/biosynthèse , Collagène de type III/biosynthèse , Fibroblastes/effets des médicaments et des substances chimiques , Fibroblastes/métabolisme , Expression des gènes , Humains , Immunohistochimie , Mâle , Modèles animaux , Antigène nucléaire de prolifération cellulaire/métabolisme , Lapins , Rats , Transduction du signal/effets des médicaments et des substances chimiques , Facteur de croissance transformant bêta-1/métabolisme
8.
CNS Neurosci Ther ; 19(1): 20-9, 2013 Jan.
Article de Anglais | MEDLINE | ID: mdl-23082997

RÉSUMÉ

AIM: To investigate the mechanism of endoplasmic reticulum (ER) stress-induced apoptosis as well as the protective action of basic fibroblast growth factor (bFGF) both in vivo and in vitro. METHODS AND RESULTS: ER stress-induced apoptosis was involved in the injuries of spinal cord injury (SCI) model rat. bFGF administration improved the recovery and increased the survival of neurons in spinal cord lesions in model rat. The protective effect of bFGF is related to the inhibition of CHOP, GRP78 and caspase-12, which are ER stress-induced apoptosis response proteins. bFGF administration also increased the survival of neurons and the expression of growth-associated protein 43 (GAP43), which is related to neural regeneration. The protective effect of bFGF is related to the activation of downstream signals, PI3K/Akt/GSK-3ß and ERK1/2, especially in the ER stress cell model. CONCLUSIONS: This is the first study to illustrate that the role of bFGF in SCI recovery is related to the inhibition of ER stress-induced cell death via the activation of downstream signals. Our work also suggested a new trend for bFGF drug development in central neural system injuries, which are involved in chronic ER stress-induced apoptosis.


Sujet(s)
Apoptose/effets des médicaments et des substances chimiques , Stress du réticulum endoplasmique/effets des médicaments et des substances chimiques , Facteur de croissance fibroblastique de type 2/usage thérapeutique , Neurones/effets des médicaments et des substances chimiques , Récupération fonctionnelle/effets des médicaments et des substances chimiques , Traumatismes de la moelle épinière , Animaux , Caspase-12/métabolisme , Modèles animaux de maladie humaine , Femelle , Protéine GAP-43/métabolisme , Protéines du choc thermique/métabolisme , Méthode TUNEL , Locomotion/effets des médicaments et des substances chimiques , Neurones/métabolisme , Cellules PC12 , Phosphatidylinositol 3-kinases , Protéines proto-oncogènes c-akt , Rats , Rat Sprague-Dawley , Indice de gravité de la maladie , Transduction du signal/effets des médicaments et des substances chimiques , Traumatismes de la moelle épinière/traitement médicamenteux , Traumatismes de la moelle épinière/anatomopathologie , Traumatismes de la moelle épinière/physiopathologie , Facteurs temps , Facteur de transcription CHOP/métabolisme , Régulation positive/effets des médicaments et des substances chimiques
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE